课题基金 / 基金详情

Biostrain - development of a novel medical device for measuring and stabilising core-muscle imbalances, from lumbar-patients to elite-athletes.

Biostrain - development of a novel medical device for measuring and stabilising core-muscle imbalances, from lumbar-patients to elite-athletes.
Biostrain - 开发一种新型医疗设备,用于测量和稳定从腰椎患者到精英运动员的核心肌肉失衡。
批准号:
10004464
负责人:
金额:
$70.74万
依托单位国家:
英国
项目类别:
Collaborative R&D
财政年份:
2021
资助国家:
英国
项目状态:
已结题
起止时间:
2021 至 --

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
**公开描述**我们经验丰富且久经考验的团队正在开发一种新型医疗设备,使临床医生和用户能够诊断和治疗已知会导致下背部疼痛、脊柱和腿筋损伤的肌肉群失衡。这项突破性的新技术将提供比现有技术更大的优势,从中风患者到背痛患者,再到矫形外科专家和业余和精英运动人士。该解决方案的市场吸引力已通过严格的客户发现得到证明。该设备使用简单,将与久经考验的医疗设备开发合作伙伴Lucid Group合作在英国国内开发、制造和分销。BioStress可应对更广泛的经济和社会挑战,包括英国工业战略和NHS预防性医疗保健的长期优先事项,专注于帮助人们保持活跃,降低对致衰性伤害的易感性。1990-2010年间,下腰痛增加了12%,尤其是在40-60岁的人群中。由此产生的生产损失成本为10,7Bn/年,而NHS的成本超过20亿GB。对于Covid的流行和在家工作的增加来说,该项目特别及时,预计未来几年由于姿势不佳,下腰痛的投诉将会增加。轻便和便携使患者可以在家中使用,而临床医生可以通过云上传来监控病情进展。在体育方面,用户将获得比任何其他腿部肌腱锻炼或监测方法更大的优势。这将使运动员和临床医生能够显著降低腿部肌腱损伤的风险,改善现有损伤的恢复,并提高健康运动员的成绩和速度。
英文摘要
**Public description**Our experienced and proven team is developing Biostrain, a novel medical device to enable clinicians and users to diagnose and treat imbalances in muscle groups known to cause lower-back pain, spinal and hamstring injuries.This groundbreaking new technology will offer major advantages over current techniques, from a wide variety of users from stroke patients to back pain sufferers, to orthopaedic specialists and amateur & elite sports-people. The market-pull for this solution have been proven through rigorous customer discovery.The device is simple to use, and will be developed, manufactured & distributed within the UK in collaboration with proven medical device development partner Lucid Group.Biostrain addresses wider economic and social challenges including UK Industrial Strategy and NHS long-term priorities for preventive healthcare, focus on helping people keep active, reducing susceptibility to debilitating injury. Lower-back-pain increased 12% 1990-2010, particularly in 40-60 year-olds. Resultant production-loss cost were £10,7Bn/year with NHS costs exceeding £2Bn. The project is particularly timely with regard to the Covid pandemic, and the increase in home-working, which is expected to produce an increase in lower back complaints in the coming years, due to poor posture.Lightweight and portability allows for patient home use whilst clinicians can monitor progression via cloud upload.In sports, users will be offered a genuine advantage over any other method of hamstring exercise or monitoring. This will enable sportspeople and clinicians to significantly reduce the risk of hamstring injury, improve recovery for existing injuries, and improve performance & speed in healthy athletes.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
损伤线粒体传递机制介导成纤维细胞/II型肺泡上皮细胞对话在支气管肺发育不良肺泡发育阻滞中的作用
  • 批准号:
    82371721
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    王星云
  • 依托单位:
增强子在小鼠早期胚胎细胞命运决定中的功能和调控机制研究
  • 批准号:
    82371668
  • 项目类别:
    面上项目
  • 资助金额:
    52.00万元
  • 批准年份:
    2023
  • 负责人:
    乔云波
  • 依托单位:
MAP2的m6A甲基化在七氟烷引起SST神经元树突发育异常及精细运动损伤中的作用机制研究
  • 批准号:
    82371276
  • 项目类别:
    面上项目
  • 资助金额:
    47.00万元
  • 批准年份:
    2023
  • 负责人:
    严佳
  • 依托单位:
"胚胎/生殖细胞发育特性激活”促进“神经胶质瘤恶变”的机制及其临床价值研究
  • 批准号:
    82372327
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    马展
  • 依托单位: